Trihexyphenidyl Expert Views

Dr. Kathryn Peall discusses the use of Trihexyphenidyl (Artane) in treating movement disorders, including its application in cerebral palsy. She notes that while the medication showed some improvement in symptoms like dystonia and chorea, it did not completely eliminate them. A notable case involved a patient with obsessive-compulsive disorder (OCD) who experienced significant improvement in OCD symptoms while being treated with Trihexyphenidyl for dystonia. This improvement was particularly impactful during the patient's school exams. Dr. Peall also highlights the challenges in measuring treatment outcomes for rare conditions like cerebral palsy, emphasizing the need for better tools to assess both motor and non-motor functions.

Dr. Charlie Fairhurst discussed the use of Trihexyphenidyl for children with dystonia, a movement disorder often associated with cerebral palsy. He noted that Trihexyphenidyl was chosen for its side effect profile, which includes improved movement. The treatment outcomes were comparable to other interventions like botulinum toxin injections, which showed improvement by a factor of 40 out of 100. Dr. Fairhurst also mentioned that oral anticholinergic medications, such as glycopyrrolate, improved conditions by about 20-22 out of 100.

Dr. Charlie Fairhurst discussed the use of Trihexyphenidyl for children with dystonia, a movement disorder often associated with cerebral palsy. He noted that Trihexyphenidyl was chosen for its side effect profile, which includes improved movement. The treatment showed similar effectiveness to other oral anticholinergic medications, improving symptoms by about 20-22 out of 100. Dr. Fairhurst also compared this to other interventions like botulinum toxin, which had a higher improvement rate of about 40 out of 100.

Riccardo Masson, a child neurologist, discusses the challenges in treating dyskinetic cerebral palsy with oral medications like Trihexyphenidyl. Dyskinetic cerebral palsy involves involuntary, disorganized movements and fluctuating muscle tone. Masson highlights that evidence for the effectiveness of first-line medications, including Trihexyphenidyl, is unclear due to inconsistent study designs, endpoints, and inclusion criteria. He emphasizes the need for better-designed trials that consider age, disorder etiology, and reliable rating scales to assess treatment effects comprehensively.